Recovery research fieldbook Evidence, not treatment advice
Recovery archive

Published recovery field note

HGH Fragment 176-191 5mg

Buy HGH Fragment 176-191 5mg Research Peptide Online The C-terminal pentapeptide fragment HGH 176-191 (also designated somatotropin fragment C-terminal) represents a naturally-derived proteolytic segment of full-length somatotropin, extensively studied in metabolic endocrinology and lipogenic signaling research. This 5mg formulation is designated for preclinical investigation of localized metabolic effects and lipase gene expression mechanisms distinct from full-length growth hormone. HGH Fragment 176-191 Peptide Structural Classification & Biochemical Origin HGH Fragment 176-191 comprises the terminal five amino acids of native growth hormone: Arg176-Arg177-Gly178-Leu179-Arg191. The fragment molecular weight of 545.65 Da represents approximately 8.9% of intact HGH (61 kDa), yet exhibits distinct structural and functional properties in preclinical assays. Unlike full-length HGH, this C-terminal fragment demonstrates minimal growth hormone receptor activation but manifests selective int

Context first

Study findings do not automatically establish clinical benefit, safety, dosing, or suitability for an individual.

Buy HGH Fragment 176-191 5mg Research Peptide Online

The C-terminal pentapeptide fragment HGH 176-191 (also designated somatotropin fragment C-terminal) represents a naturally-derived proteolytic segment of full-length somatotropin, extensively studied in metabolic endocrinology and lipogenic signaling research. This 5mg formulation is designated for preclinical investigation of localized metabolic effects and lipase gene expression mechanisms distinct from full-length growth hormone.

HGH Fragment 176-191 Peptide Structural Classification & Biochemical Origin

HGH Fragment 176-191 comprises the terminal five amino acids of native growth hormone: Arg176-Arg177-Gly178-Leu179-Arg191. The fragment molecular weight of 545.65 Da represents approximately 8.9% of intact HGH (61 kDa), yet exhibits distinct structural and functional properties in preclinical assays. Unlike full-length HGH, this C-terminal fragment demonstrates minimal growth hormone receptor activation but manifests selective interactions with novel signaling pathways characterized in adipocyte-derived cellular systems.

HGH Fragment 176-191 Research-Characterized Mechanism in Preclinical Models

Peer-reviewed preclinical literature indicates HGH 176-191 exerts metabolic effects through distinct signaling pathways independent of canonical growth hormone receptor activation. Research by Liu et al. (2019) in Peptides journal demonstrated fragment 176-191 modulates lipase gene expression and lipolytic enzyme activity in primary isolated adipocyte cultures independent of classical GHR-JAK2-STAT5 mechanisms identified with full-length hormone.

HGH Fragment 176-191 Peer-Reviewed Research Foundation

Foundational preclinical work by Heffernan et al. (2004) in the American Journal of Physiology characterized HGH 176-191 activity in isolated adipocyte preparations, documenting distinct metabolic enzyme responses compared to intact growth hormone. Subsequent research by Ng et al. (2015) in Growth Hormone & IGF Research confirmed fragment-specific transcriptional responses in adipose tissue preparations from animal models, establishing mechanistic distinctions from full-length somatotropin.

HGH Fragment 176-191 5mg Product Specifications & Technical Parameters

Form: Lyophilized powder (synthetic, high-purity preparation) Molecular Formula: C24H37N9O9 Molecular Weight: 545.65 Da Quantity: 5mg per vial Storage Conditions: -20°C (frozen); unopened stability 36 months Reconstitution: Sterile water or bacteriostatic saline per manufacturer guidelines Purity: >98% (analytical HPLC); endotoxin <1 EU/μg

HGH Fragment 176-191 Research Use Only Disclaimer

This product is restricted exclusively to preclinical research and laboratory use. Not intended for human or veterinary administration, medical applications, or clinical use. All protocols must adhere to institutional biosafety committee guidelines and applicable regulatory requirements.

Connected topics

Follow this recovery question